The Zhitong Finance App learned that on Friday, City Therapeutics (CTY.US) entered the US stock market. As of press release, the stock had risen nearly 24% to $22.315. The IPO price is $18. City Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, USA. It was founded in 2023 and focuses on developing next-generation RNA interference (RNAi) therapies to treat diseases with significant unmet medical needs by inhibiting specific disease-related protein expression. The company's core R&D pipeline includes CITY-FXI for preventing thromboembolic diseases, City-RBP4 for treating the hereditary retinal disease Stargardt disease, and CITY-TFR2 for chronic disease-related anemia. Among them, CITY-FXI has entered phase I clinical trials. The company was founded by senior experts in the field of RNAi. The co-founder and executive chairman John Maraganore was the CEO of AlnyLam, a pioneer in RNAi pharmaceuticals.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.